Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB

June 6, 2012

GOTHENBURG, Sweden, June 7, 2012 /PRNewswire/ –

Cellectricon is pleased to announce the appointment of Paul Karila as the company’s
Head of Discovery Services. Dr. Karila brings a solid and highly impressive neuroscience
discovery track record to Cellectricon, important for the company’s expansion in bringing
state-of-the-art discovery services to market. Paul has extensive experience of the drug
discovery industry and has held several management positions at AstraZeneca.

The Company’s Discovery Services will be based on the proprietary Cellaxess(R) Elektra
platform for automated cellular electric field manipulation enabling novel screening
applications in the CNS and Cardiovascular therapeutic fields.

Cellectricon’s CEO David Burns said: “Cellectricon is delighted with the appointment
of Dr. Karila. We are looking forward to working with Paul’s experience and direction to
broaden our cell-based CNS and Cardiovascular Discovery Services using the Company’s
strong IP and technology position to accelerate discovery through collaborations with our
pharmaceutical partners”.

Dr. Karila added: “Cellectricon has a strong reputation in the discovery industry with
equally strong customer validation and well-earned reputation for providing groundbreaking
products and services to the pharmaceutical and life science research markets. Working
with the strong scientific team, I will focus on further developing and providing
outstanding cell-based discovery services to our customers to accelerate their drug
discovery and biological research. ”

Cellectricon is a leading provider of advanced cell-based screening technologies and
services to accelerate drug discovery and cell-based assay research. Our proprietary
technologies include leading systems for high resolution ion-channel screening and cell
engineering. Developed in close collaboration with leaders in the pharmaceutical industry
and esteemed research labs, the Cellaxess(R) Technology enables scalable field
stimulation, compound delivery and transfection for genomic screening of primary cells,
neurones and stem cells. The Dynaflow(R) Technology advances ion channel research and
discovery applications.

http://www.cellectricon.com

SOURCE Cellectricon AB


Source: PR Newswire